The addition of atezolizumab to bevacizumab, carboplatin, and paclitaxel delayed progression or death compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.
OncLive.comAtezolizumab/Bevacizumab Combo Improves PFS for Untreated Advanced NSCLC #lcsm
This JAMA Clinical Guidelines Synopsis summarizes the 2017 American College of Cardiology/American Heart Association guideline on prevention, detection, evaluation, and management of high blood pressure in adults.
<p>Fry <i>et al</i>. report the first results from a human trial of a CD22-directed chimeric antigen receptor (CAR) T cell therapy providing evidence of efficacy in the treatment of pre–B cell acute lymphoblastic leukemia that is immunotherapy-naive...
A phase II trial of savolitinib, a MET inhibitor, found that the drug induced partial responses in some patients with papillary renal cell carcinoma and was well tolerated, prompting drug makers Chi-Med and AstraZeneca to launch a phase III study.